

DCF Psychotropic Medication Advisory Committee
Monthly Meeting Notes

October 7, 2011 at 1:00PM
Riverview Hospital for Children and Youth
Middletown, CT.

PRESENT: David Aresco, Pharmacist; M. Waqar Azeem, M.D.; Patricia Cables, APRN; Jason Gott, Pharmacist; Jacqueline Harris, M.D.; Irvin Jennings, M.D.; Monica Jensen, RN; Aurele Kamm, APRN; Lesley Siegel, M.D.; Amy Veivia, Pharmacist; Curtis Harmon, APRN; Chris Malinowski, APRN; Beth Muller, APRN; Joan Narad, M.D.; Heather Kissinger, Pharmacist.

1. Call to order: Dr. Siegel called the meeting to order at 1:14 pm.
2. Next Meeting: The next meeting will take place on Friday November 4, 2011 at 1:00.
3. Minutes: June 2011 meeting minutes were amended with corrections made to the DCF PMAC Bylaws. (attached)
4. Announcements: There will be a name change for Riverview Hospital for Children and Youth. The new name will be "Albert J. Solnit Children's Psychiatric Center".
5. Connecticut Retrospective DUR Report: Presented by Heather Kissinger, PharmD. A document containing the key points of this report was distributed (attached). A detailed report was then presented by Dr. Kissinger. It was noted that there is more information on the DSS web site (www.ctdssmap.com). Once on the site click on the RxBottle. Additionally 2 quarterly reports will be attached to these minutes: Metabolic Syndrome and Polypharmacy.
 - Several possible reports that could be gleaned from the DSS claims database were suggested and discussed.
 - Cost report: a report to show total Medicaid drug cost vs. the cost of psychotropics that would compare 2008 to the most recent annual data available.
 - Underutilization report: show patients on multiple atypicals or other class of medication with one or more not dosed adequately.

It was noted that Connecticut is the only state that performs retrospective DUR for patients <18 yrs old.

A recommendation was made to have Value Behavioral Health come to a PMAC meeting and present their final report. It was agreed that a sample patient profile will be sent to Dr. Siegel by Dr. Kissinger.

It was noted that the next DUR board meeting will take place at the Ct. Pharmacist Association in Rocky Hill CT on December 8, 2011 at 6:30pm. All are invited to attend.

6. DCF PMAC Bylaws: Approved as amended (see attached).
7. Citalopram (Celexa): FDA Drug Safety Communication posted 08/24/2011.
 - A copy of the alert was distributed, reviewed and discussed. The recommendation to change the dosing guideline from a maximum dose of 60mg/day to 40mg/day was approved.
 - Issues surrounding EKG will be deferred to the next meeting as part of the 6month review of the Psychotropic Medication Use Guidelines.
 - Withdrawal issues relating to all SSRI's will be researched and results presented at the next meeting.
8. Quetiapine (Seroquel): FDA label change posted 07/18/2011.
 - A copy of the FDA label change was distributed, reviewed, and discussed. The recommendation to make no change and enforce the current DCF PMAC maximum dose and monitoring guidelines was approved.
9. Overview of Drug Information Inquiries June – September 2011:
 - Safety profile comparison between Intuniv and Kapvay: for Kapvay there are no label data, no studies, and no case reports available. Intuniv data is available for adults however results were not clinically significant. No recommendations made based on this information.
 - Poly-pharmacy with antipsychotic medications: the Joint Commission definition was presented and discussed. An opinion from Dr. Van Wattum was discussed. His opinion is that there is no rationale or benefit from polypharmacy but there is an increase in side effects in the pediatric population.
10. The remaining agenda items are deferred to the next meeting and the meeting was adjourned at 3pm.

Respectfully Submitted:

David S. Aresco